Skip to main content
FeaturePress Release

CTT Pharma Updates On Worldwide Patent Portfolio

By December 8, 2022April 11th, 2023No Comments


CTT Pharma Updates On Worldwide Patent Portfolio

Tampa, Florida, United States – The Newswire – December 19, 2022 – CTT Pharmaceutical Holdings, Inc.(OTC:CTTH) has received patent approval in Israel for our dissolvable strip technology. This latest patent approval gives CTT up to 48 granted patents, including three patents in the United States, three in Canada, Europe, Australia, South Africa, Mexico, and Israel. Europe covers up to 38 countries, which includes The United Kingdom, Germany, France, Switzerland, and Italy to name a few.
CTT also has 9 patents pending, which includes four patents pending in the United States, three in Canada, Brazil, and Chile. In 2021 CTT secured pending patents in the US and Canada to cover Psychedelics using our technology and in 2022 CTT strengthened our patents by filing a continuation from an existing granted US Patent to broaden protection for Nicotine, Vitamins, and Caffeine. The nicotine patents were a priority for CTT as they offer a smoke-free alternative to smoking or vaping and would be one of the few oral nicotine products on the market, that dissolve in your mouth in seconds. CTT also recently filed two new patents in the US and two in Canada to further strengthen existing patents offering protection for Pharmaceuticals, Nicotine, Vitamins, and other medicinal actives.

Ryan Khouri, CEO of CTT Pharma, stated that we have made a tremendous amount of progress with our patents in a short period of time. Furthermore, these patents give CTT the ability to align with partners that have a global reach.

About CTT Pharma
Our patented technology offers protection using many different APIs on dissolvable strips and in other oral deliverables. CTT successfully received Health Canada approval for our dissolvable strips and sold out in weeks with no advertising. CTT’s dissolvable strips enter the bloodstream once dissolved in the mouth, bypassing the lungs and digestive tract, allowing for better absorption, faster onset, as fast as an injection, and the ability to combine products.

CTT will continue to update shareholders as more news becomes available .

CTT Pharma – 813-606-0060